Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice

Authors

  • Randy L. Hunter,

    1. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
    Search for more papers by this author
    • The first two authors contributed equally to this work.

  • Baohua Cheng,

    1. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
    2. Department of Human Anatomy, School of Medicine, Shandong University, Jinan City, People's Republic of China
    Search for more papers by this author
    • The first two authors contributed equally to this work.

  • Dong-Young Choi,

    1. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
    Search for more papers by this author
  • Mei Liu,

    1. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
    Search for more papers by this author
  • Shuwei Liu,

    1. Department of Human Anatomy, School of Medicine, Shandong University, Jinan City, People's Republic of China
    Search for more papers by this author
  • Wayne A. Cass,

    1. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
    Search for more papers by this author
  • Guoying Bing

    Corresponding author
    1. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
    • Department of Anatomy and Neurobiology, University of Kentucky, Chandler Medical Center, 800 Rose Street, Medical Center MN208, Lexington, KY 40536-0298
    Search for more papers by this author

Abstract

A role for inflammation has been hypothesized in the etiology and progression of Parkinson's disease (PD). In this study, we generated, characterized, and validated the first progressive PD-related mouse model (C57/B6) with intrastriatal injection of lipopolysaccharide (LPS). We showed progressive and specific dopaminergic neurodegeneration in the substantia nigra, which is accompanied by striatal dopamine depletion and progressive behavioral impairment, which was alleviated by the use of the PD drug L-Dopa. We focused on the role of nitric oxide (NO) in inflammation-promoted cell death and suggest that the expression of the inducible NO synthase plays a role in the progressive loss of dopaminergic neurons but not the initial loss induced by LPS. With this model, future research can be performed in gene knockout mice to study other potential mechanisms of inflammation-induced neurodegeneration. In addition, this model can be used to screen therapeutics for PD at a more clinically relevant time (i.e., after LPS injection but before manifestation of PD-related behavioral impairment), because most PD drugs are screened in animal models in which inhibitors are given predisease induction. Thus, this novel PD-related model should be further characterized and strongly considered as a tool for future drug studies. © 2009 Wiley-Liss, Inc.

Ancillary